Kim MY, Sohn KH, Song WJ, Park HW, Cho SH, Min KU, et al. Clinical features and prognostic factors of Churg-Strauss syndrome. Korean J Intern Med. 2014;29:85–95.
Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet. 2003;361:587–94.
Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65:270–81.
Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003;115:284–90.
Moosig F, Bremer JP, Hellmich B, Holle JU, Holl-Ulrich K, Laudien M, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72:1011–7.
Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol. 2007;19:25–32.
Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52:2926–35.
Zwerina J, Eger G, Englbrecht M, Manger B, Schett G. Churg-Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patients. Semin Arthritis Rheum. 2009;39:108–15.
Bacciu A, Bacciu S, Mercante G, Ingegnoli F, Grasselli C, Vaglio A, et al. Ear, nose and throat manifestations of Churg-Strauss syndrome. Acta Otolaryngol. 2006;126:503–9.
Healy B, Bibby S, Steele R, Weatherall M, Nelson H, Beasley R. Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strauss syndrome. J Allergy Clin Immunol. 2013;131(571–6):e1-6.
Ashman PE, Chen T, Barinsky GL, Benson B, Babu S, Bojrab DI 2nd, et al. Otologic manifestations of eosinophilic granulomatosis with polyangiitis: a systematic review. Otol Neurotol. 2021;42:e380–7.
Ishiyama A, Canalis RF. Otological manifestations of Churg-Strauss syndrome. Laryngoscope. 2001;111:1619–24.
Ueki S, Yamauchi H, Takeda M, Chihara J. Eosinophilic granuloma of the middle ear. J Rheumatol. 2011;38:2005–6.
Wierzbicka M, Szyfter W, Puszczewicz M, Borucki L, Bartochowska A. Otologic symptoms as initial manifestation of wegener granulomatosis: diagnostic dilemma. Otol Neurotol. 2011;32:996–1000.
Cottin V, Bel E, Bottero P, Dalhoff K, Humbert M, Lazor R, et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Eur Respir J. 2016;48:1429–41.
Seccia V, Fortunato S, Cristofani-Mencacci L, Dallan I, Casani AP, Latorre M, et al. Focus on audiologic impairment in eosinophilic granulomatosis with polyangiitis. Laryngoscope. 2016;126:2792–7.
Cho HJ, Yune S, Seok JM, Cho EB, Min JH, Seo YL, et al. Clinical characteristics and treatment response of peripheral neuropathy in the presence of eosinophilic granulomatosis with polyangiitis (Churg-Strauss Syndrome): experience at a single tertiary center. J Clin Neurol. 2017;13:77–83.
Nagamine H, Iino Y, Kojima C, Miyazawa T, Iida T. Clinical characteristics of so called eosinophilic otitis media. Auris Nasus Larynx. 2002;29:19–28.
Bewick V, Cheek L, Ball J. Statistics review 13: receiver operating characteristic curves. Crit Care. 2004;8:508–12.
Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art. Allergy. 2013;68:261–73.
Jardel S, Puechal X, Le Quellec A, Pagnoux C, Hamidou M, Maurier F, et al. Mortality in systemic necrotizing vasculitides: a retrospective analysis of the French Vasculitis Study Group registry. Autoimmun Rev. 2018;17:653–9.
Tsurikisawa N, Oshikata C, Kinoshita A, Tsuburai T, Saito H. Longterm prognosis of 121 patients with eosinophilic granulomatosis with polyangiitis in Japan. J Rheumatol. 2017;44:1206–15.
Cohen P, Pagnoux C, Mahr A, Arene JP, Mouthon L, Le Guern V, et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007;57:686–93.
Ribi C, Cohen P, Pagnoux C, Mahr A, Arene JP, Lauque D, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 2008;58:586–94.
Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, Ruoppolo G, et al. Churg-Strauss syndrome. Autoimmun Rev. 2015;14:341–8.
Iino Y. Eosinophilic otitis media: a new middle ear disease entity. Curr Allergy Asthma Rep. 2008;8:525–30.
Thornton JL, Chevallier KM, Koka K, Gabbard SA, Tollin DJ. Conductive hearing loss induced by experimental middle-ear effusion in a chinchilla model reveals impaired tympanic membrane-coupled ossicular chain movement. J Assoc Res Otolaryngol. 2013;14:451–64.
Goldfarb JM, Rabinowitz MR, Basnyat S, Nyquist GG, Rosen MR. Head and neck manifestations of eosinophilic granulomatosis with polyangiitis: a systematic review. Otolaryngol Head Neck Surg. 2016;155:771–8.
Breslin NK, Heindel NH, Haberman RS. Role of interleukin 5 inhibition in the treatment of eosinophilic otitis media. OTO Open. 2021;5:2473974X2199144.
Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther. 2011;33:1413–32.
Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75:952–7.
Khoury P, Grayson PC, Klion AD. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol. 2014;10:474–83.
McBrien CN, Menzies-Gow A. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Drugs Today (Barc). 2018;54:93–101.
Okada M, Suemori K, Takagi D, Teraoka M, Yamada H, Ishizaki J, et al. The treatment outcomes of rituximab for intractable otitis media with ANCA-associated vasculitis. Auris Nasus Larynx. 2019;46:38–42.
留言 (0)